No Data
No Data
No Data
No Data
No Data
Disappointing Week for Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Institutional Investors Who Control 28% of the Company
Key Insights Institutions' substantial holdings in Dianthus Therapeutics implies that they have significant influence over the company's share price 56% of the business is held by the top 6 sharehol
Simply Wall StApr 22 08:13 ET
Dianthus Therapeutics Is Maintained at Outperform by Raymond James
Dianthus Therapeutics Is Maintained at Outperform by Raymond James
Dow JonesApr 18 13:15 ET
Dianthus Therapeutics Price Target Raised to $51.00/Share From $34.00 by Raymond James
Dianthus Therapeutics Price Target Raised to $51.00/Share From $34.00 by Raymond James
Dow JonesApr 18 13:15 ET
Express News | Dianthus Therapeutics Inc : Raymond James Raises Target Price to $51 From $34: Raymond James Raises Target Price to $51 From $34
Moomoo 24/7Apr 18 07:12 ET
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. ("Dianthus"), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement
GlobeNewswireApr 5 16:30 ET
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Yahoo FinanceMar 27 08:19 ET
No Data
No Data
I-am-ToTh :
BuyHighSellLow88 : Are you looking for someone to buy your shares or why are you posting this here?
AGeezy : where did you find this news?
Jaguar8 : Current short shares available now is approximately 16M shares
nilos Wayne BuyHighSellLow88: yes
View more comments...